{
  "ticker": "LLY",
  "target_date": "2025-09-01",
  "actual_date": "2025-08-29",
  "collected_at": "2025-12-08T12:13:11.940108",
  "price": {
    "open": 731.25,
    "high": 736.34,
    "low": 727.43,
    "close": 731.5057373046875,
    "volume": 2551200,
    "change_1d_pct": 0.08,
    "change_7d_pct": 3.85,
    "change_30d_pct": -4.86
  },
  "technicals": {
    "rsi_14": 83.83,
    "sma_20": 699.64,
    "sma_50": 746.03,
    "macd": -4.804,
    "macd_signal": -13.113,
    "macd_histogram": 8.309,
    "bb_upper": 785.47,
    "bb_lower": 613.82,
    "price_vs_sma20_pct": 4.55,
    "price_vs_sma50_pct": -1.95,
    "volume_ratio": 0.38
  },
  "fundamentals": {
    "market_cap": 892261367808,
    "pe_ratio": 48.766293,
    "forward_pe": 43.924095,
    "price_to_book": 37.4744,
    "price_to_sales": 15.01623,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.49,
    "pct_from_52w_low": 59.56
  },
  "macro": {
    "spy": {
      "price": 643.27,
      "change_1d_pct": -0.6,
      "change_7d_pct": 1.49
    },
    "vix": {
      "level": 15.36,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.23
    },
    "dollar_index": {
      "level": 97.77
    },
    "gold": {
      "price": 3473.7
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Pfizer's Golden Cross Signals Strength: How to Play the Stock",
      "source": "Yahoo",
      "datetime": 1756745940,
      "summary": "Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=766b7bbe3cfaf3f14842b487bb761254e5a7e1e7add1dbf89f118fba2d7c5ac2"
    },
    {
      "headline": "NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?",
      "source": "Yahoo",
      "datetime": 1756742040,
      "summary": "Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.",
      "url": "https://finnhub.io/api/news?id=ceb21b4812e5cfe77c54ab66cfe1da8cd81e2d4678188228fb78195e689b8daa"
    },
    {
      "headline": "Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi",
      "source": "Yahoo",
      "datetime": 1756740660,
      "summary": "BIIB wins FDA approval for Leqembi Iqlik, a fast, subcutaneous option for early Alzheimer's patients transitioning from IV infusions.",
      "url": "https://finnhub.io/api/news?id=5fcb22efe784c3c1bc1390055a3abba44f55bffbec9fbdb7de18c979e53736ab"
    },
    {
      "headline": "ESC 2025: Novo Nordisk\u2019s Wegovy superior to Zepbound in reducing CV events",
      "source": "Yahoo",
      "datetime": 1756731308,
      "summary": "In the real-world trial, Novo Nordisk's Wegovy showed a significant reduction in cardiovascular events compared to Eli Lilly\u2019s Zepbound.",
      "url": "https://finnhub.io/api/news?id=3ca7ef78fa9f953fb29a971b405c7612e31a7433f4952cfbca51e7bc9f9b467c"
    },
    {
      "headline": "ESC 2025: Study supports use of semaglutide, tirzepatide in cardiometabolic HFpEF patients",
      "source": "Yahoo",
      "datetime": 1756728697,
      "summary": "The findings presented highlighted that patients initiating semaglutide or tirzepatide had more than 40 % lower risk of hospitalisation for heart failure (HF) or all-cause mortality compared to sitagliptin.",
      "url": "https://finnhub.io/api/news?id=0283f3e9222ff393de1a50a83ce101d42fae671e9af6febe4915124c7b2cd6cd"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412129.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000236/xslF345X05/wk-form4_1756412129.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412046.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000234/xslF345X05/wk-form4_1756412046.xml"
    },
    {
      "form": "8-K",
      "date": "2025-08-20",
      "description": "d929636d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634943.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000230/xslF345X05/wk-form4_1755634943.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}